Published in J Affect Disord on October 01, 1998
Recruitment of the left hemispheric emotional attention neural network in risk for and protection from depression. J Psychiatry Neurosci (2013) 0.79
Anhedonia is associated with blunted reward sensitivity in first-degree relatives of patients with major depression. J Affect Disord (2015) 0.76
Biphasic development of carrageenin edema in rats. J Pharmacol Exp Ther (1969) 4.24
Genome-wide, large-scale production of mutant mice by ENU mutagenesis. Nat Genet (2000) 3.92
Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo. Mol Psychiatry (2008) 3.85
Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts. Mol Psychiatry (2008) 3.68
Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet (1998) 3.42
Differential signal transduction by five splice variants of the PACAP receptor. Nature (1993) 3.38
Neuroactive steroids: mechanisms of action and neuropsychopharmacological perspectives. Trends Neurosci (1999) 2.76
Lifetime and six-month prevalence of mental disorders in the Munich Follow-Up Study. Eur Arch Psychiatry Clin Neurosci (1992) 2.68
Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology (2000) 2.36
Neuroprotection against oxidative stress by estrogens: structure-activity relationship. Mol Pharmacol (1997) 2.16
Reduced glutamate in the anterior cingulate cortex in depression: an in vivo proton magnetic resonance spectroscopy study. Biol Psychiatry (2000) 2.14
Brain activation and hypothalamic functional connectivity during human non-rapid eye movement sleep: an EEG/fMRI study. Brain (2005) 2.07
Molecular characterization and functional analysis of the leukocyte surface protein CD31. J Immunol (1990) 2.07
Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci (2000) 2.06
Low lumbar bone mineral density in patients with major depression. Am J Psychiatry (1994) 2.05
TMEM132D, a new candidate for anxiety phenotypes: evidence from human and mouse studies. Mol Psychiatry (2010) 2.00
The combined dexamethasone/CRH test: a refined laboratory test for psychiatric disorders. J Psychiatr Res (1995) 1.94
Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res (2000) 1.89
Toxic hepatitis by clozapine treatment. Am J Psychiatry (1993) 1.83
17-beta estradiol protects neurons from oxidative stress-induced cell death in vitro. Biochem Biophys Res Commun (1995) 1.80
A multicenter measurement of magnetization transfer ratio in normal white matter. J Magn Reson Imaging (1999) 1.76
Diurnal variations in the human host response to endotoxin. J Infect Dis (1996) 1.71
Brain oxytocin inhibits basal and stress-induced activity of the hypothalamo-pituitary-adrenal axis in male and female rats: partial action within the paraventricular nucleus. J Neuroendocrinol (2000) 1.51
Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II. Biol Psychiatry (1995) 1.49
The Munich vulnerability study on affective disorders: premorbid psychometric profile of affected individuals. Acta Psychiatr Scand (2004) 1.46
Solventogenic enzymes of Clostridium acetobutylicum: catalytic properties, genetic organization, and transcriptional regulation. FEMS Microbiol Rev (1995) 1.45
Patterns of response to repeated total sleep deprivations in depression. J Affect Disord (2001) 1.44
IL2RA and IL7RA genes confer susceptibility for multiple sclerosis in two independent European populations. Genes Immun (2008) 1.43
Behavioral, neuroendocrine, and cardiovascular response to flumazenil: no evidence for an altered benzodiazepine receptor sensitivity in panic disorder. Biol Psychiatry (1999) 1.42
Dissociated central and peripheral release of vasopressin, but not oxytocin, in response to repeated swim stress: new insights into the secretory capacities of peptidergic neurons. Neuroscience (1998) 1.42
Major bleeding complications after cardiopulmonary resuscitation: impact of thrombolytic treatment. J Intern Med (2003) 1.42
Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J Neuroendocrinol (2002) 1.41
V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. J Neurosci (1995) 1.39
Altered hypothalamic-pituitary-adrenocortical regulation in healthy subjects at high familial risk for affective disorders. Neuroendocrinology (1995) 1.38
Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry (1998) 1.38
Anxiety: a potential predictor of vulnerability to the initiation of ethanol self-administration in rats. Psychopharmacology (Berl) (1995) 1.35
Quantification of regional intrapulmonary oxygen partial pressure evolution during apnea by (3)He MRI. J Magn Reson (1999) 1.34
Behavioural performance in three substrains of mouse strain 129. Brain Res (1997) 1.33
Regional blood flow, capillary permeability, and compartmental volumes: measurement with dynamic CT--initial experience. Radiology (1999) 1.32
[A scale for the objective evaluation of the state of subjective well-being as a method for longitudinal studies]. Arzneimittelforschung (1970) 1.31
Cellular localization of interleukin 6 mRNA and interleukin 6 receptor mRNA in rat brain. Eur J Neurosci (1993) 1.31
Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. a prospective study. J Psychiatr Res (2001) 1.31
"Anxietas tibiarum". Depression and anxiety disorders in patients with restless legs syndrome. J Neurol (2005) 1.31
Persistent neuroendocrine and behavioral effects of a novel, etiologically relevant mouse paradigm for chronic social stress during adolescence. Psychoneuroendocrinology (2007) 1.29
Pharmacological and functional characterization of human mineralocorticoid and glucocorticoid receptor ligands. Eur J Pharmacol (1993) 1.28
Corticotropin-releasing hormone receptor subtypes and emotion. Biol Psychiatry (1999) 1.28
The neurosteroid tetrahydroprogesterone counteracts corticotropin-releasing hormone-induced anxiety and alters the release and gene expression of corticotropin-releasing hormone in the rat hypothalamus. Neuroscience (1994) 1.28
Dose-dependent effects of endotoxin on human sleep. Am J Physiol Regul Integr Comp Physiol (2000) 1.26
Stress responsive neurohormones in depression and anxiety. Pharmacopsychiatry (2003) 1.24
Glucocorticoids enhance oxidative stress-induced cell death in hippocampal neurons in vitro. Endocrinology (1997) 1.23
Neither major depression nor glucocorticoid treatment affects the cellular integrity of the human hippocampus. Eur J Neurosci (2001) 1.22
Direct targeting of hippocampal neurons for apoptosis by glucocorticoids is reversible by mineralocorticoid receptor activation. Mol Psychiatry (2005) 1.19
The limited utility of the dexamethasone suppression test for the diagnostic process in psychiatry. Br J Psychiatry (1984) 1.19
Hippocampal apoptosis in major depression is a minor event and absent from subareas at risk for glucocorticoid overexposure. Am J Pathol (2001) 1.19
Repetitive transcranial magnetic stimulation increases the release of dopamine in the mesolimbic and mesostriatal system. Neuropharmacology (2002) 1.18
Progesterone receptor-mediated effects of neuroactive steroids. Neuron (1993) 1.18
Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends Neurosci (1995) 1.16
Neuroprotection by estrogens in a mouse model of focal cerebral ischemia and in cultured neurons: evidence for a receptor-independent antioxidative mechanism. J Cereb Blood Flow Metab (1999) 1.16
Amphetamines induce apoptosis and regulation of bcl-x splice variants in neocortical neurons. FASEB J (1999) 1.16
Therapeutic effects of GABA-ergic drugs in affective disorders. A preliminary report. Pharmacol Biochem Behav (1983) 1.15
Genetic variation in FKBP5 associated with the extent of stress hormone dysregulation in major depression. Genes Brain Behav (2013) 1.15
Conditional mouse mutants highlight mechanisms of corticotropin-releasing hormone effects on stress-coping behavior. Mol Psychiatry (2008) 1.15
Placental glucose transporter expression is regulated by glucocorticoids. J Clin Endocrinol Metab (1999) 1.13
Prediction of medium-term outcome by cortisol response to the combined dexamethasone-CRH test in patients with remitted depression. Am J Psychiatry (1999) 1.12
Hormonal response pattern in the combined DEX-CRH test is stable over time in subjects at high familial risk for affective disorders. Neuropsychopharmacology (1998) 1.12
Blunted corticotropin and normal cortisol response to human corticotropin-releasing factor in depression. N Engl J Med (1984) 1.12
Depression, comorbidities and the TNF-alpha system. Eur Psychiatry (2008) 1.12
HPA-axis regulation at in-patient admission is associated with antidepressant therapy outcome in male but not in female depressed patients. Psychoneuroendocrinology (2008) 1.12
Progesterone induces changes in sleep comparable to those of agonistic GABAA receptor modulators. Am J Physiol (1996) 1.11
Relationship between clinical pain complaints and pain sensitivity in patients with depression and panic disorder. Psychosom Med (2000) 1.11
Prenatal immune challenge alters the hypothalamic-pituitary-adrenocortical axis in adult rats. J Clin Invest (1994) 1.11
A comparison of two diagnostic methods. Clinical ICD diagnoses vs DSM-III and Research Diagnostic Criteria using the Diagnostic Interview Schedule (version 2). Arch Gen Psychiatry (1985) 1.10
Pituitary-adrenal-system regulation and psychopathology during amitriptyline treatment in elderly depressed patients and normal comparison subjects. Am J Psychiatry (1996) 1.10
Neuropeptide S receptor gene -- converging evidence for a role in panic disorder. Mol Psychiatry (2010) 1.09
Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology (2000) 1.09
Subtle shifts in the ratio between pro- and antiapoptotic molecules after activation of corticosteroid receptors decide neuronal fate. FASEB J (2000) 1.09
Exacerbation of apoptosis in the dentate gyrus of the aged rat by dexamethasone and the protective role of corticosterone. Exp Neurol (1996) 1.09
Pain perception in psychiatric disorders: a review of the literature. J Psychiatr Res (1994) 1.08
Chronic treatment of rats with the antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology (1993) 1.08
Chronic infusion of a CRH1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul Pept (1995) 1.08
Gene expression and function of interleukin 1, interleukin 6 and tumor necrosis factor in the brain. Prog Neurobiol (1994) 1.08
Serial assessment of corticotropin-releasing hormone response after dexamethasone in depression. Implications for pathophysiology of DST nonsuppression. Biol Psychiatry (1987) 1.08
Effects of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacology (1998) 1.07
Association between the insulin-induced gene 2 (INSIG2) and weight gain in a German sample of antipsychotic-treated schizophrenic patients: perturbation of SREBP-controlled lipogenesis in drug-related metabolic adverse effects? Mol Psychiatry (2008) 1.07
Behavioural profiles of two Wistar rat lines selectively bred for high or low anxiety-related behaviour. Behav Brain Res (1998) 1.06
Soluble interleukin-6 (IL-6) receptor augments central effects of IL-6 in vivo. FASEB J (1995) 1.06
A novel chronic social stress paradigm in female mice. Horm Behav (2010) 1.06
Cortisol, ACTH, and cardiovascular response to a cognitive challenge paradigm in aging and depression. Am J Physiol (1995) 1.05
Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. Mol Endocrinol (1993) 1.05
Forced swimming evokes a biphasic response in CREB phosphorylation in extrahypothalamic limbic and neocortical brain structures in the rat. Eur J Neurosci (2002) 1.05
Genome-wide association analysis of copy number variation in recurrent depressive disorder. Mol Psychiatry (2011) 1.05
gamma-Glutamylglutamine and taurine concentrations are decreased in the cerebrospinal fluid of drug-naive patients with schizophrenic disorders. J Neurochem (1995) 1.04